Leader

Ataxia telangiectasia gene mutations in leukaemia and lymphoma

J Boultwood

Leukaemia Research Fund Molecular Haematology Unit, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, UK

Correspondence to:
Dr Boultwood jboultwo{at}enterprise.molbiol.ox.ac.uk

Ataxia telangiectasia (AT) is a rare multisystem, autosomal, recessive disease characterised by neuronal degeneration, genome instability, and an increased risk of cancer. Approximately 10% of AT homozygotes develop cancer, mostly of the lymphoid system. Lymphoid malignancies in patients with AT are of both B cell and T cell origin, and include Hodgkin's lymphoma, non-Hodgkin's lymphoma, and several forms of leukaemia. The AT locus was mapped to the chromosomal region 11q22–23 using genetic linkage analysis in the late 1980s and the causative gene was identified by positional cloning several years later. The ATM gene encodes a large protein that belongs to a family of kinases possessing a highly conserved C-terminal kinase domain related to the phosphatidylinositol 3-kinase domain. Members of this kinase family have been shown to function in DNA repair and cell cycle checkpoint control following DNA damage. Recent studies indicate that ATM is activated primarily in response to double strand breaks and may be considered a caretaker of the genome. Most mutations in ATM result in truncation and destabilisation of the protein, but certain missense and splicing errors have been shown to produce a less severe phenotype. AT heterozygotes have a slightly increased risk of breast cancer. Atm deficient mice exhibit many of the symptoms found in patients with AT and have a high frequency of thymic lymphoma. The association between mutation of the ATM gene and a high incidence of lymphoid malignancy in patients with AT, together with the development of lymphoma in Atm deficient mice, supports the proposal that inactivation of the ATM gene may be of importance in the pathogenesis of sporadic lymphoid malignancy. Loss of heterozygosity at 11q22–23 (the location of the ATM gene) is a common event in lymphoid malignancy. Frequent inactivating mutations of the ATM gene have been reported in patients with rare sporadic T cell prolymphocytic leukaemia (T-PLL), B cell chronic lymphocytic leukaemia (B-CLL), and most recently, mantle cell lymphoma (MCL). In contrast to the ATM mutation pattern in AT, the most frequent nucleotide changes in these sporadic lymphoid malignancies were missense mutations. The presence of inactivating mutations, together with the deletion of the normal copy of the ATM gene in some patients with T-PLL, B-CLL, and MCL, establishes somatic inactivation of the ATM gene in the pathogenesis of lymphoid malignancies, and strongly suggests that ATM functions as a tumour suppressor. The presence of missense mutations in the germline of patients with B-CLL has been reported, suggesting that some patients with B-CLL may be constitutional AT heterozygotes. The putative hereditary predisposition of B-CLL, although intriguing, warrants further investigation.

Key Words: lymphoid malignancy • mutation • ataxia telangiectasia gene

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Ashworth, A. (2008). A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair. JCO 26: 3785-3790 [Abstract] [Full Text]  
• Joshi, A. D., Hegde, G. V., Dickinson, J. D., Mittal, A. K., Lynch, J. C., Eudy, J. D., Armitage, J. O., Bierman, P. J., Bociek, R. G., Devetten, M. P., Vose, J. M., Joshi, S. S. (2007). ATM, CTLA4, MNDA, and HEM1 in High versus Low CD38 Expressing B-Cell Chronic Lymphocytic Leukemia. Clin. Cancer Res. 13: 5295-5304 [Abstract] [Full Text]  
• Maclean, K. H., Kastan, M. B., Cleveland, J. L. (2007). Atm Deficiency Affects Both Apoptosis and Proliferation to Augment Myc-Induced Lymphomagenesis. Mol Cancer Res 5: 705-711 [Abstract] [Full Text]  
• Kaufmann, W. K., Filatov, L., Oglesbee, S. E., Simpson, D. A., Lotano, M. A., McKeen, H. D., Sawyer, L. R., Moore, D. T., Millikan, R. C., Cordeiro-Stone, M., Carey, L. A. (2006). Radiation clastogenesis and cell cycle checkpoint function as functional markers of breast cancer risk. Carcinogenesis 27: 2519-2527 [Abstract] [Full Text]  
• Allam, A., Kabelitz, D. (2006). TCR trans-Rearrangements: Biological Significance in Antigen Recognition vs the Role as Lymphoma Biomarker. J. Immunol. 176: 5707-5712 [Abstract] [Full Text]  
• Greiner, T. C., Dasgupta, C., Ho, V. V., Weisenburger, D. D., Smith, L. M., Lynch, J. C., Vose, J. M., Fu, K., Armitage, J. O., Braziel, R. M., Campo, E., Delabie, J., Gascoyne, R. D., Jaffe, E. S., Muller-Hermelink, H. K., Ott, G., Rosenwald, A., Staudt, L. M., Im, M. Y., Karaman, M. W., Pike, B. L., Chan, W. C., Hacia, J. G. (2006). Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc. Natl. Acad. Sci. USA 103: 2352-2357 [Abstract] [Full Text]  
• Payne, S. R., Kemp, C. J. (2005). Tumor suppressor genetics. Carcinogenesis 26: 2031-2045 [Abstract] [Full Text]  
• Karnitz, L. M., Flatten, K. S., Wagner, J. M., Loegering, D., Hackbarth, J. S., Arlander, S. J. H., Vroman, B. T., Thomas, M. B., Baek, Y.-U., Hopkins, K. M., Lieberman, H. B., Chen, J., Cliby, W. A., Kaufmann, S. H. (2005). Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell Survival. Mol. Pharmacol. 68: 1636-1644 [Abstract] [Full Text]  
• Winrow, C. J., Pankratz, D. G., Vibat, C. R. T., Bowen, T.J., Callahan, M. A., Warren, A. J., Hilbush, B. S., Wynshaw-Boris, A., Hasel, K. W., Weaver, Z., Lockhart, D. J., Barlow, C. (2005). Aberrant recombination involving the granzyme locus occurs in Atm-/- T-cell lymphomas. Hum Mol Genet 14: 2671-2684 [Abstract] [Full Text]  
• TUTT, A.N.J., LORD, C.J., MCCABE, N., FARMER, H., TURNER, N., MARTIN, N.M., JACKSON, S.P., SMITH, G.C.M., ASHWORTH, A. (2005). Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer. Cold Spring Harb Symp Quant Biol 70: 139-148 [Abstract]  
• Lumsden, J. M., McCarty, T., Petiniot, L. K., Shen, R., Barlow, C., Wynn, T. A., Morse, H. C. III, Gearhart, P. J., Wynshaw-Boris, A., Max, E. E., Hodes, R. J. (2004). Immunoglobulin Class Switch Recombination Is Impaired in Atm-deficient Mice. JEM 200: 1111-1121 [Abstract] [Full Text]  
• Rollinson, S., Allan, J. M., Law, G. R., Roddam, P. L., Smith, M. T., Skibola, C., Smith, A. G., Forrest, M. S., Sibley, K., Higuchi, R., Germer, S., Morgan, G. J. (2004). High-Throughput Association Testing on DNA Pools to Identify Genetic Variants that Confer Susceptibility to Acute Myeloid Leukemia. Cancer Epidemiol. Biomarkers Prev. 13: 795-800 [Abstract] [Full Text]  
• Wilkens, L., Flemming, P., Gebel, M., Bleck, J., Terkamp, C., Wingen, L., Kreipe, H., Schlegelberger, B. (2004). Induction of aneuploidy by increasing chromosomal instability during dedifferentiation of hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 101: 1309-1314 [Abstract] [Full Text]  
• Lingaas, F., Comstock, K. E., Kirkness, E. F., Sorensen, A., Aarskaug, T., Hitte, C., Nickerson, M. L., Moe, L., Schmidt, L. S., Thomas, R., Breen, M., Galibert, F., Zbar, B., Ostrander, E. A. (2003). A mutation in the canine BHD gene is associated with hereditary multifocal renal cystadenocarcinoma and nodular dermatofibrosis in the German Shepherd dog. Hum Mol Genet 12: 3043-3053 [Abstract] [Full Text]  
• Fang, N. Y., Greiner, T. C., Weisenburger, D. D., Chan, W. C., Vose, J. M., Smith, L. M., Armitage, J. O., Mayer, R. A., Pike, B. L., Collins, F. S., Hacia, J. G. (2003). Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proc. Natl. Acad. Sci. USA 100: 5372-5377 [Abstract] [Full Text]  
• Chenevix-Trench, G., Dork, T., Scott, C., Hopper, J. (2002). RESPONSE: Re: Dominant Negative ATM Mutations in Breast Cancer Families. JNCI J Natl Cancer Inst 94: 952-952 [Full Text]